Literature DB >> 16455327

Microscopically incomplete resection offers acceptable palliation in pancreatic cancer.

Koert Kuhlmann1, Steve de Castro, Tjarda van Heek, Olivier Busch, Thomas van Gulik, Hugo Obertop, Dirk Gouma.   

Abstract

BACKGROUND: Because mortality and morbidity of pancreatic surgery have decreased to acceptable levels, the complex question arises whether pancreatic resection should be performed in patients with preoperatively doubtful resectable pancreatic cancer.
METHODS: Perioperative parameters and outcome of 80 patients who underwent a microscopically incomplete (R1) resection were compared with those of 90 patients who underwent a bypass for locally advanced disease for pancreatic adenocarcinoma. All patients initially underwent exploratory laparotomy with the intention to perform a resection. Quality of life was assessed by analyzing readmissions and their indications.
RESULTS: Groups were similar with respect to age, presenting symptoms, and preoperative health status. Tumors were significantly larger in the bypass group (3.5 cm vs 2.9 cm, P < .01). Hospital mortality was comparable: zero after R1 resection and 2% after bypass. Of all severe complications, only intra-abdominal hemorrhage occurred significantly more frequently after resection (10% vs 2%; P = .03). Hospital stay after resection was significantly longer than after bypass (16 vs 10 days; P < .01). Survival was significantly longer after R1 resection (15.8 vs 9.5 months, P < .01). Sixty-one percent of patients were readmitted for a total of 215 admissions, equally distributed between groups. After R1 resection, 0.58% of the total survival time after initial discharge was spent in the hospital, after bypass, 0.69%, which was not significantly different.
CONCLUSIONS: R1 pancreatic resection and bypass for locally advanced disease can be performed with comparable low mortality and morbidity rates. Readmission rates are also comparable between groups and time spent in the hospital after initial discharge is low. Because resection offers adequate palliation in pancreatic cancer, a more aggressive surgical approach in patients who are found to have a doubtfully resectable tumor could be advocated, even if only an R1 resection can be achieved.

Entities:  

Mesh:

Year:  2006        PMID: 16455327     DOI: 10.1016/j.surg.2005.06.034

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  17 in total

Review 1.  Surgical palliation in patients with pancreatic cancer.

Authors:  Jörg Köninger; Moritz N Wente; Michael W Müller; Carsten N Gutt; Helmut Friess; Markus W Büchler
Journal:  Langenbecks Arch Surg       Date:  2006-11-11       Impact factor: 3.445

2.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

3.  Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.

Authors:  Yasuhiro Fujino; Tetsuya Sakai; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2008-03-29       Impact factor: 7.527

4.  Gastro-pancreaticostomy using a tube stent as a less invasive palliative treatment for malignant obstructive pancreatitis.

Authors:  Mizuki Ninomiya; Ken Shirabe; Akinobu Taketomi; Tadahiro Nozoe; Takashi Maeda; Hideaki Nakashima; Akito Matsukuma; Takahiro Ezaki; Yoshihiko Maehara
Journal:  Surg Today       Date:  2011-05-28       Impact factor: 2.549

5.  Management of pancreatic cancer: current status and future directions.

Authors:  H Ramesh
Journal:  Indian J Surg       Date:  2010-11-16       Impact factor: 0.656

6.  Management of pancreatic cancer: Current status and future directions.

Authors:  H Ramesh
Journal:  Indian J Surg       Date:  2010-01-13       Impact factor: 0.656

7.  Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil?

Authors:  Michael Tachezy; Maximilian Bockhorn; Florian Gebauer; Yogesh K Vashist; Jussuf Thomas Kaifi; Jakob Robert Izbicki
Journal:  J Gastrointest Surg       Date:  2011-02-26       Impact factor: 3.452

8.  Margin positive pancreaticoduodenectomy is superior to palliative bypass in locally advanced pancreatic ductal adenocarcinoma.

Authors:  Harish Lavu; Andres A Mascaro; Dane R Grenda; Patricia K Sauter; Benjamin E Leiby; Sean P Croker; Agnes Witkiewicz; Adam C Berger; Ernest L Rosato; Eugene P Kennedy; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2009-09-16       Impact factor: 3.452

9.  Pancreatic carcinoma: palliative surgical and endoscopic treatment.

Authors:  D J Gouma; O R C Busch; T M Van Gulik
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

10.  Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.

Authors:  Younghwan Kim; Song Cheol Kim; Ki Byoung Song; Jayoun Kim; Dae Ryong Kang; Jae Hoon Lee; Kwang-Min Park; Young-Joo Lee
Journal:  HPB (Oxford)       Date:  2016-02-08       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.